Objective: Driving regulations for people with seizures vary widely throughout the United States and the world. Maryland updated their guidelines in 2003 to reflect those of a U.S. consensus guideline requiring a minimum 3-month seizure-free period as well as an individual risk assessment by a Medical Advisory Board (MAB). This retrospective study provides the first analysis of outcomes after the implementation of the consensus guidelines and an assessment of their predictive validity through longitudinal outcome data. Methods: MAB reviews and licensing records for Maryland driver applicants with seizures between 2004 and 2005 were reviewed, during which 254 first-time applicants were processed. The initial licensing decisions were assessed and the subsequent seizure recurrence and crash rates over the following 7 years were evaluated. Results: The MAB approved driving for 74.8% of initial applicants; most had been seizure-free for over 6 months. Approved drivers had a longer median seizure-free period (563 days) compared to those who were denied (104.5 days, p < 0.01), and 22.7% of approved drivers had seizures recur during monitoring over the next year, although none resulted in crashes or deaths. Of applicants initially denied (n = 50), 89.3% were eventually licensed. Treating physicians recommended driving for 84.4% of applicants rejected by the MAB. Significance: Maryland's individualized system for assessing driving applicants with seizures resulted in a dynamic process of approvals and denials based on favorable and unfavorable risk factors and lengths of seizure freedom. Seizure recurrences were comparable to internationally accepted rates. Over the course of monitoring, most applicants were eventually licensed. Treating physicians recommended that nearly all their patient applicants be permitted to drive, which raises safety concerns for the 10 states that rely solely on physician recommendations. Further assessment is needed of the risk factors deemed favorable and unfavorable by the U.S. consensus guidelines.
pose a low risk to public safety and to themselves. 4 U.S. laws are generally less restrictive compared to other countries, [5] [6] [7] [8] [9] [10] [11] although individual state laws vary widely, particularly in their seizure-free period requirements. 12 The American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation have developed model consensus guidelines for regulating drivers with seizures, recommending a seizure-free period of at least 3 months as well as individualized assessments by a state Medical Advisory Board (MAB). 13, 14 Eighteen states revised their driving regulations over the past 13 years, mainly by shortening the minimum seizurefree requirements from 1 year to 3-6 months and including additional screening by MABs or the treating physician (Table 1) . 12, 13, 15, 16 The changes generally reflect the recommended driving guidelines. Currently, however, there are limited data on the actual implementation of these consensus guidelines and whether the guidelines adequately balance public safety risks while allowing patients with controlled seizures to drive. 4, 6, 15 We assessed outcomes in Maryland after the U.S. consensus guidelines were implemented. Historically, Maryland had a 1-year seizure-free requirement. In 1985, the laws were revised, requiring that all drivers be reinstated after a 90-day seizure-free period regardless of whether "unfavorable modifiers," such as treatment noncompliance or structural brain lesions, 17, 18 were present. After a highly publicized seizure-induced fatal crash, the regulations were adjusted in 2003 to mirror those of the U.S. consensus guidelines and to promote individualized determinations by a MAB. 19 The U.S. consensus guidelines delineate several "favorable" and "unfavorable" modifiers to be considered by state MABs when evaluating individuals with seizures to determine whether to modify the recommended seizurefree interval of 3 months. 13 These were adapted by the Maryland Motor Vehicle Administration's (MVA) MAB. 19 Examples of favorable modifiers include seizures during medically directed medication changes, simple partial seizures that do not interfere with consciousness or motor control, seizures with consistent and prolonged auras, and pure nocturnal seizures. Unfavorable modifiers include noncompliance with medication or medical visits, alcohol or drug abuse in the past 3 months, and structural brain lesions. We tabulated such seizure risk factors and characterized licensing decisions made in Maryland between 2004 and 2005 after the implementation of the U.S. consensus guidelines. Clinical factors associated with approval or denial of licensing and subsequent seizure recurrence rates and seizure-related crash rates were evaluated. We also compared assessments made by the treating physicians on their patients' driving safety profiles with those of the MAB. This is the first study of its type to assess the actual, pragmatic implementation of a regulatory process on drivers with seizures and provide longitudinal outcome data to assess its effectiveness.
Methods

Study population
We studied Maryland driver applicants who had newly reported histories of epilepsy or seizures over a 2-year period (2004) (2005) . These applicants included new driver applicants, licensed drivers first reporting seizures, and drivers referred by police, physicians, or others. We collected follow-up data from MVA monitoring for up to 7 years.
MVA referral and review
The referral and review process for drivers coming to the attention of the Maryland MVA medical review unit has been described previously. 20 Cases are prepared and managed by MVA administrative nurse case reviewers, who then review cases with the MAB or consult protocols promulgated by the MAB.
Data collection
We used a Maryland MVA database to identify new driver applicants with seizures between 2004 and 2005. We recorded demographic information and clinical variables from affidavits and medical questionnaires submitted by applicants and their physicians. Follow-up data from each MAB review was collected for up to 7 years (through 2012), including changes in licensure and monitoring requirements. To evaluate for crashes, all drivers' MVA records were reviewed for a full 7 years.
Study approval
The study was approved by the Johns Hopkins University Institutional Review Board (IRB) and conducted at the central MVA branch with a waiver of consent. Applicant data was de-identified at the MVA using patient codes with identifying information removed. Patient codes and data were Key Points • A U.S. consensus epilepsy driving guideline recommends a minimum 3-month seizure-free period with modifiers and review by a Medical Advisory Board
• After the guideline was applied in Maryland, 75% of drivers were licensed: 23% had seizure recurrence in the first year, but with no seizure-related crashes/ deaths
• Over 7 years, only two seizure-related crashes were reported, which is comparable to internationally accepted rates
• Treating physicians recommended driving for 85% of applicants denied licenses by the Motor Vehicle Administration (MVA), raising concern for safety in states that rely solely on physician review stored at the MVA in a locked cabinet. The study analysis was conducted at the Johns Hopkins University and the University of Maryland Schools of Medicine.
Statistical and analysis methods
We compared demographic and clinical variables for denied and approved applicants for the 7-year study period to examine clinical factors associated with driving decisions and seizure recurrence. We profiled MAB and treating physician assessments and MAB monitoring requirements.
To minimize the effects of monitoring exemptions on analyses of clinical associations, we analyzed licensing and seizure recurrence 1 year after initial application. Chi-square tests and analysis of variance (ANOVA) were used to compare clinical variables gathered at the initial review with the MAB decisions and seizure recurrence.
Results
Characteristics of driver applicants with seizures
During a 2-year period, 254 Maryland drivers applied to the MVA for licensure and reported a history of seizures.
Fifty-seven percent of applicants were male, with a median age of 33 (range 15-86) ( Table 2 ); 32.7% of applicants were young (<22 years), whereas 8.7% were senior adults (>60 years old). Most (91.3%) of the applicants resided in urban or suburban areas, mainly in two major Maryland metropolitan areas, the Baltimore central region (39.3%) and the District of Columbia capital region (30.2%).
Most applicants reporting seizures (90.7%) were treated with antiepileptic drugs (AEDs), including 73.8% on monotherapy and 26.2% on polytherapy. Eighty-nine applicants (35%) had at least one major comorbidity, most commonly central nervous system (CNS) injury (17.7% of applicants), cardiovascular disease (11.8%), and non-substance-abuse psychiatric disorders (10.6%) ( Table 2) .
Most applicants (95.3%) were self-referred; 4.7% were reported by the police. Although physician reporting of drivers with epilepsy in Maryland is protected by civil litigation immunity, 12 there were no physician referrals to the MVA. Half (50.8%) of the drivers applying reported being seizure-free for >1 year at the time of their first MAB review. Nineteen percent had been seizure-free for 6-12 months, 14.5% for 3-6 months, and 15.7% for <90 days. The median seizure-free interval was 370 days for all applicants (range 0-35 years) ( Table 3) .
Clinical variables associated with drivers' licensing
Three fourths (74.8%) of the 254 first-time applicants were approved by the MAB to drive ( Table 3 ). The strongest clinical factor associated with approval was a long seizure-free interval: approved drivers had a median seizure-free period of 563 days (range 0-35 years), whereas denied applicants had a median seizure-free interval of 104.5 days (range 21-1,423 days). For licensure, the MAB required that most applicants be seizure-free >6 months: 83.9% of approved drivers had seizure-free periods over 6 months, whereas 72.5% of denied applicants had shorter seizure-free periods (p < 0.01;
. 43.5% of those denied were seizurefree <3 months.
Other clinical factors were more variable between those approved and denied. Denied applicants more frequently had histories of diabetes (p = 0.012; v 2 = 6.33, d.f. = 1) or substance abuse (p < 0.01; v 2 = 11.3, d.f. = 1) compared to approved drivers (Table 3 ). Most drivers referred by the police were not approved for licensure during their first review (p = 0.018; v 2 = 5.61, d.f. = 1). MAB requirements for formal follow-up monitoring varied based on applicant seizure-free periods and the presence of clinical risk factors, but were not standardized. A minority of applicants (16.1%; n = 41), typically those with very long periods of seizure remission (median seizure-free period 5.4 years), were licensed and exempted at their initial reviews from additional formal monitoring, but were instructed to report any seizure recurrences to the MVA. Long-term licensing and seizure outcomes The 254 applicants were followed for a median of 2.1 years (range 0-7 years). Approximately two thirds (160/254, 63%) of the driving applicants completed at least one annual MAB review (Table 4) . A total of 60 individuals were exempted from further monitoring either at initial review (n = 41) or within the first year of monitoring (n = 19), and thus did not have review data at 1 year. Excluding these individuals, loss to follow-up at 1 year was 17.5% (34/194) .
One fourth (40/160, 25%) of the applicants who completed an MAB review at 1 year reported they had seizures during their first year of monitoring. Seizure recurrence was slightly higher in those denied licensure (15/50, 30%) compared to approved applicants (25/110, 22.7%). If the 60 individuals who were exempt from further monitoring during the first year (none of whom reported seizure recurrences) are included, the rate of seizure recurrence for approved drivers decreases to 14.7% (25/170).
Many applicants shifted between being approved and denied licensure during the study period; 23.8% (n = 41) of those initially approved to drive at some later time had driving privileges revoked due to seizures (excluding 18 drivers lost to MAB follow-up) (Fig. 1) . Most (87.5%) of the 64 applicants initially denied licensure reapplied to drive after a median period of 182 days (range 5 days to 6.7 years). The majority (n = 50; 89.3%) were eventually approved to drive by the MAB (Fig. 1) , usually after seizure-free periods >6 months. Of initial applicants, 55.6% were exempted from further MAB monitoring at some point in the 7-year study period, with 90% of those exempted having been seizure-free for >1 year. Although drivers exempted by the MAB from further reviews were instructed to report recurrent seizures, none were reported by the drivers, medical providers, or police.
Licensed applicants who remained seizure-free during their first year of monitoring had longer seizure-free intervals (median 275 days) at initial application compared to those who had seizures (median 145 days); however, this difference was not statistically significant due to variability in the groups (Table 4) . Clinical factors not associated with an increased risk of seizure recurrence in monitored drivers included AED treatment, changes in AED regimen, a history of substance abuse, and the presence of medical comorbidities such as diabetes.
Although many drivers reported seizures during the study period, few crashes were reported. No crashes were reported in the first 3 years of MAB monitoring. The police referred four drivers to the MAB 3-7 years after initial reviews: two had seizures associated with crashes with no injuries reported, another had medication toxicity and crashed, and the last had an observed seizure while driving but did not crash.
Driving risk assessments by treating physicians
Treating physicians reported excellent prognosis in 51.7% of applicants denied licensure by the MAB and in 56.9% approved to drive. Treating physicians did not report a poor prognosis in any patient, and overall their ratings of fair/good/excellent prognoses in patients had no correlation with MAB approvals. Seizures were often minimized as single "breakthroughs" due to illness, stress, or medication changes. Treating physicians reported that nearly all patients (99.1%) were adherent to AED treatments, despite previous studies indicating much higher proportions of nonadherence. 21 They also reported that only 15.9% of their patients were not fit to drive ("physically and mentally capable of driving"); 87.3% of applicants the MAB denied licensure were reported as fit to drive by their treating physicians.
Applying U.S. consensus guidelines: individualized risk assessments
Consistent with the U.S. consensus guidelines, Maryland required a minimum 3-month seizure-free interval, and the MAB performed individualized seizure and crash risk assessments to determine whether to modify this requirement. The favorable and unfavorable risk factors delineated by the U.S. consensus guidelines were applied by the Maryland MAB to help determine the seizure-free time period required for individual applicants.
13 Thirty-six applicants were seizure-free between 3 and 6 months, of whom 18 were approved to drive. Twelve of these individuals had only positive modifying risk factors, such as simple partial seizures, prolonged auras, or nocturnal seizures. Of the 18 applicants denied licensure, eight had negative modifying risk factors.
Discussion
Maryland's review system for regulating driving for applicants with seizures assesses individual risks and reflects a U.S. consensus guideline. The approval process is dynamic: most initial applicants with long seizure-free periods were licensed, and those with long remissions were exempted from further MVA monitoring. Most of the applicants initially denied licensure were later approved once seizures were better controlled. Some drivers with recurring seizures had their licenses rescinded.
Overall, the approval and denial process of driving privileges in individuals with seizures appears to meet general safety goals while still permitting most applicants to drive; 74.8% of applicants were approved with their first application, and no crashes were reported in the first 3 years. Within the 7-year monitoring period, two crashes resulted from seizures and one crash was linked to medication toxicity.
None of the drivers who were initially approved and were exempted from further MAB monitoring subsequently reported seizures. This raises a concern that some may not be reporting their seizures. 22 In a previous risk study, we found that despite a legal requirement to report seizures to the MVA, nearly one half of patients do not report their condition. 4 Mandatory physician reporting is not recommended by the consensus guideline because of concern that it may negatively impact a patient-physician relationship, as seen in a 2003 California survey study where 50% of patients concealed information from their physicians about their seizures. 23 However, the Maryland MAB, as is the case in most states, does recommend that physicians report patients who may represent a high public safety risk.
This review of a state system did not include an assessment of licensing for commercial drivers. In the U.S., the Federal Motor Carrier Safety Administration sets standards for interstate commercial driving. Until recently, regulations denied commercial licenses to any individual with a diagnosis of epilepsy or individuals on antiseizure medication. Updated regulations now permit commercial licensing exemptions after 8 years of seizure freedom with or without medication treatment with annual medical evaluations. 24 However, there does remain a concern that in order to maintain commercial licensure, some of these applicants may not be truthful in reporting seizure recurrences.
Evaluation by treating physicians is an integral part of the Maryland review system. Of interest, their recommendations often deviated from the MAB, providing favorable safety ratings for about 85% of the individuals ultimately denied licensure. Physicians often reported occasional seizures as isolated "breakthrough" events due to exceptional stress or illness, and reported the patient's epilepsy to be controlled with a good prognosis. Treating physicians also reported that <1% of their patients had missed AED doses even though a previous Maryland study found that 20% of drivers occasionally missed AED doses and 20% missed doses immediately prior to having seizures related to crashes. 4 No physicians directly notified the MVA of their patients' seizures despite this being legally protected and evidence that physician reporting could be beneficial for public safety. 8, 25 Given these discrepancies, the judgment of physicians may be overly influenced by their patients' strong desire to drive. 22, 26 This highlights a potential problem in the 10 states where treating physicians directly determine whether patients may drive and possibly in the 18 states in which they make driving recommendations (Table 1) . 12 Although seizure recurrences were relatively frequent in licensed drivers, it is reassuring that few crashes and no serious injuries or deaths were reported. This is consistent with prior studies showing that drivers with controlled epilepsy do not pose a large safety risk to the public. [27] [28] [29] [30] [31] In support of this, the Arizona mandatory seizure-free interval for licensing was shortened from 12 to 3 months with no resulting increase in seizure-related crash frequency. 15 That study, which is the only other U.S. study on the incidence of actual crashes due to seizures, found crash rates of approximately 0.75% crashes/population/year. This is similar to our own results derived from a smaller population of 254, where there were only two seizure-related crashes over 7 years (approximately 0.11% crashes/population/year).
Our retrospective study characterized driver applicants with epilepsy and the MVA driving review process with seizure and crash outcomes. The study was limited by not being a prospective epidemiologic study and by not evaluating drivers who did not report their condition to the MVA. Patients with intermittent seizures, such as those with partially or completely controlled seizures, may be less likely to self-report their condition and be underrepresented in our analysis. The Maryland MAB also exempted many patients with long seizure-free intervals and only favorable prognostic factors from further monitoring. This is consistent with the U.S. consensus guidelines, which states that "periodic review may not be necessary if the state requires individuals to report seizures . . . (and) has a mechanism for regular license renewal. . .."
13 It is a limitation that seizure recurrence data in exempt patients were not collected, but given that the median seizure-free period was relatively long in these patients (median 5.4 years in those exempted at initial review), these data are not likely to influence the outcome significantly. Most drivers were monitored for 1 year or more and provided information on seizure recurrence. This study was not designed to analyze all the specific reasons for acceptance or denial of licenses by the MAB; however, we were able to show that the seizure-free interval was a major determinant, and that seizure-free restrictions were shortened or lengthened according to the presence or absence of favorable and unfavorable risk factors. Another limitation is that police crash reports are not linked to the patients' MAB medical reports. The police may not suspect that crashes are linked to seizures unless a seizure is directly witnessed or personal injury has occurred and a medical history is obtained.
The dynamic pattern of approvals and denials of licensure over the course of the MAB monitoring period challenged our ability to track seizures and driving outcomes. However, the ability to adjust licensing decisions based on an individual's changing clinical history over time appears to be a strength of this system and should be a focus of future studies comparing regulatory approaches. There are three general regulatory approaches currently implemented in the U.S.: 26 states require fixed mandatory seizure-free intervals ranging from 3 to 12 months, 17 states provide individualized assessments with no fixed seizure-free requirements, and 8 states, including Maryland, incorporate the hybrid approach recommended by the regulatory guidelines (Table 1) . Little evidence exists as to which system is optimal for limiting risks for seizure-related crashes, although severe restrictions may result in decreased adherence to patient self-reporting and compliance. 32, 33 The MAB considered many risk factors in determining licensure; however, the significance of several of these favorable and unfavorable risk factors (e.g., having long auras or only nocturnal seizures), is uncertain and warrants further study. 4 ,13,34,35 
Applicants approved to drive without formal MAB follow-up were not included in the outcome analysis for this Studies have shown that seizure-free intervals of at least 6-12 months are associated with reduced odds for seizurerelated crashes. 4 The observed seizure recurrence risk for approved drivers in Maryland's hybrid regulatory approach appeared to be within risk ranges accepted by other regulatory groups. In the United Kingdom and some parts of the European Union, a seizure-recurrence risk of <20% over 1 year is proposed as an acceptable risk for driving. 6, 10, 11 This is comparable to the rate noted in our study of 22.7%, which decreases to 14.7% if long-term seizure-free patients exempted from monitoring at initial review or within the first year of monitoring were assumed to remain seizurefree. None of these exempted patients self-reported seizure recurrence despite instructions to do so should seizures recur. Still, seizure rates generally serve only as a surrogate for the true public safety danger marked by seizure-related crashes. Although such crash rates have rarely been reported in the literature, our findings of two accidents associated with seizures in 7 years appears to be within previously reported and accepted ranges. 4, 15, 36 Further evaluation of the impact of possible risk factors in crash and driving outcomes might help MABs more accurately assess individual applicant seizure and crash risks. Partially to respond to these study observations, the Maryland MVA administration recently implemented the following: (1) clearer standards for exempting drivers from follow-up; (2) more explicit language reminding drivers to report seizure recurrences; (3) automated police reporting of suspected seizure-related crashes; and (4) an Internetbased system that encourages physicians to report patients to the MAB who may present public safety risks. States that depend on treating physicians to assess driving may wish to Each horizontal bar represents an applicant. Black bars on the left show seizure-free intervals at initial application. Vertical ticks on bars represent a MAB review. Driving approval status is represented for a 5-year study period grouped by initial review decisions as "approved and exempt," "approved," and "denied" from MAB monitoring. Epilepsia ILAE determine whether they underestimate seizure risks, as appeared to be the case in Maryland.
